High plasma interleukin-6 is associated with drug-eluting stent thrombosis - Possible role of inflammatory cytokines in the development of stent thrombosis from the Korea stent thrombosis registry

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1350-1357

  Hwang, Seok Jae ^a,c   Park, Kyung Woo ^a   Kwon, Dong A ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Chae, In Ho ^b   Gwon, Hyeon Cheol ^d   Park, Seung Jung ^e   Seung, Ki Bae ^f   Ahn, Taehoon ^g   Yoon, Jung Han ^h   Jang, Yang Soo ⁱ   Jeong, Myung Ho ^j   Tahk, Seung Jea ^k   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Asan Medical Center   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Gachon University College of Medicine   (South Korea)

^h Wonju Severance Christian Hospital   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Chonnam National University Medical School   (South Korea)

^k Ajou University Medical Center   (South Korea)

more..

Author keywords

Drug eluting stent (DES); Interleukins; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; CLOPIDOGREL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ELUTING STENT; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHI-SQUARE DISTRIBUTION; DRUG-ELUTING STENTS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; REGISTRIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79957766198     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0488     Document Type: Article

References (32)

1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
2. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
3. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drugeluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
4. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
5. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
7. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
8. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: A potential treatment strategy for drug-eluting stents. Circulation 2006; 114: 1512-1521.
9. Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, MacRae AR, et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem 2007; 53: 2112-2118.
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
11. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
12. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
13. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, et al. Long-term follow-up of neointimal coverage of sirolimuseluting stents: Evaluation with optical coherence tomography. Circ J 2009; 73: 2300-2307.
14. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
15. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236.
16. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, et al. Rapamycin, but Not FK-506, increases endothelial tissue factor expression implications for drug-eluting stent design. Circulation 2005; 112: 2002-2011.
17. Stähli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M, et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 2006; 99: 149-155.
18. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, et al. Prognostic impact of preprocedural C reactive protein levels on 6- month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007; 93: 1087-1092.
19. Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, et al. Comparison of effects of bare metal versus drugeluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006; 97: 1473-1477.
20. Sardella G, Mariani P, D'Alessandro M, De Luca L, Pierro M, Mancone M, et al. Early elevation of interleukin-1B and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res 2006; 117: 659-664.
21. Kang WC, Ahn TH, Moon CI, Han SH, Shin EK, Kim JS, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 2009; 95: 970-975.
22. Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous intervention. Heart Vessels 2008; 23: 75-82.
23. Munk PS, Breland UM, Aukrust P, Skadberg O, Ueland T, Larsen AI. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis 2011; 31: 92-98.
24. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
25. Narahara N, Enden T, Wiiger M, Prydz H. Polar expression of tissue factor in human umbilical vein endothelial cells. Arteriorscler Thromb 1994; 14: 1815-1820.
26. Yesner LM, Huh HY, Pearce SF, Silverstein RL. Regulation of monocyte CD36 and thrombospondin expression by soluble mediators. Arterioscler Thromb Vasc Biol 1996; 16: 1019-1025.
27. Lyberg T, Stanley ER, Prydz H. Colony stimulating factor-1 induces thromboplastin activity in murine macrophages and human monocytes. J Cell Physiol 1987; 132: 367-370.
28. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-283.
29. Undas A, Szuldrzyński K, Brummel-Ziedins KE, Tracz W, Zmudka K, Mann KG. Systemic blood coagulation activation in acute coronary syndromes. Blood 2009; 113: 2070-2078.
30. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
31. Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31: 1172-1180.
32. Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol 2010; 55: 1936-1942.